Botulinum toxin type A therapy for blepharospasm

This review (3 RCTs; n=313) concludes with moderate certainty that a single treatment resulted in a clinically relevant reduction of blepharospasm-specific severity and disability. There are no data from RCTs on repeated injection cycles.

Source:

Cochrane Database of Systematic Reviews